ArticleClinical epigenetics2026
Mendelian randomization reveals DNA methylation-related pyroptosis genes associated with psoriasis risk.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResearch has indicated a connection between pyroptosis and psoriasis, yet the specific genes involved remain largely unidentified. This study employed Mendelian randomization (MR) to evaluate the potential causal impact of both pyroptosis-related genes and DNA methylation signatures on psoriasis risk.
methodsPyroptosis-related genes were sourced from the GeneCards database. We integrated quantitative trait locus (QTL) data, including expression (eQTLs), DNA methylation (mQTLs), and protein expression (pQTLs). The GCST90014456 database provided genome-wide association study (GWAS) data for psoriasis, using the FinnGen and UKB cohorts for validation. Summary data-based Mendelian randomization (SMR) analysis assessed interactions between these genes and psoriasis, while colocalization analysis identified shared causal genetic variants.
resultsSMR analysis identified 82 methylation sites, 18 gene, and 2 protein were associated with psoriasis risk. Multi-omics integration highlighted ADAR, which increased methylation at cg27530370 was associated with decreased ADAR expression (OR = 0.505, 95% CI [0.421-0.607]). Additionally, DNMT3B, PROM2, and KIF11 were the intersection genes of mQTL and eQTL analysis, and were validated by the UKB cohort in eQTL analysis, and NFKB1 was validated by the UKB cohort in pQTL analysis.
conclusionThis multi-omics analysis reveals that pyroptosis-related genes, particularly ADAR, DNMT3B, PROM2, KIF11, and NFKB1, may be involved in psoriasis development, providing important insights into its molecular mechanisms and potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.